Related Experiment Video
Updated: Jun 4, 2025
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
Post-COVID-19 inflammation and sarcopenia in obese diabetic dialysis patients
Carlos Alexandre Ferreira de Oliveira1, Livia Maria Borges Amaral1, José Pedro Cassemiro Micheleto1
1Faculty of Medicine, Federal University of Alagoas, Maceió, Brazil.
Insights
This study found no significant differences in sarcopenia risk or inflammatory markers between dialysis patients with and without COVID-19. Elevated parathyroid hormone (PTH) was noted in one group, suggesting complex interactions in this patient population.
Area of Science:
- Nephrology
- Infectious Diseases
- Endocrinology
Background:
- Diabetes, obesity, and chronic kidney disease (CKD) negatively affect musculoskeletal health.
- These conditions increase the risk of severe outcomes from coronavirus disease 2019 (COVID-19).
Purpose of the Study:
- To investigate the association between COVID-19 status and sarcopenia risk in dialysis patients.
- To examine inflammatory markers and body composition in relation to COVID-19 in this population.
Main Methods:
- Cross-sectional study of 32 dialysis patients, divided by COVID-19 status.
- Assessed inflammatory markers (IL-1β, IL-6, IL-8, TNF-α), sarcopenia risk (SARC-F, bioimpedance, muscle strength), and parathyroid hormone (PTH).
Main Results:
- No significant differences in inflammatory markers or sarcopenia risk between COVID-19 positive and negative groups.
- Body composition and muscle strength were comparable, with the exception of elevated PTH levels in one group (p=0.008).
Conclusions:
- The lack of a clear association between inflammation and sarcopenia may be due to the pre-existing inflammatory state in patients with diabetes, CKD, and obesity.
- Elevated PTH levels were the primary significant laboratory finding differentiating the groups.
Introduction:
Diabetes, obesity, and CKD collectively impact musculoskeletal health and increase the risk of severe coronavirus disease 2019 (COVID-19) outcomes.
Methods:
This cross-sectional study included 32 dialysis patients, categorized based on their COVID-19 status. Laboratory assessments included inflammatory markers (IL-1β, IL-6, IL-8, and TNF-α). Sarcopenia risk was evaluated using the strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) questionnaire, bioimpedance analysis, and static muscle strength testing.
Results:
No significant differences were observed between groups in laboratory values, sarcopenia risk, or inflammatory markers. Body composition, SARC-F scores, and static muscle strength were comparable across both groups, except for elevated parathyroid hormone (PTH) levels in Group A (p = 0.008).
Conclusion:
The lack of association between the inflammatory response and sarcopenia risk may be attributed to the existing inflammatory status of this population, given the coexistence of diabetes, CKD, and obesity. Notably, all studied laboratory variables showed no significant differences, except for the higher PTH levels.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
13:35Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
Published on: March 21, 2021
